Seeking Alpha

Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee...

Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee meeting to review the company's new-drug application for its pancreatitis drug RG1068. The drug developer says it expects the FDA to request additional clinical-trial data.
Comments (1)
  • francis williams
    , contributor
    Comments (25) | Send Message
     
    I'm just me, not smart enough to see the above coming. I'm not high on cold showers.
    26 Apr 2012, 11:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector